Published in:
Open Access
24-01-2024 | Aplastic Anemia | Original Research
Letermovir Effectively Prevents Cytomegalovirus Infection in Patients with Aplastic Anemia After Hematopoietic Stem Cell Transplantation: A Real-World Retrospective Cohort Study
Authors:
Yuling Zhang, Xiaowei Chen, Ming Zhou, Yuping Zhang, Cunte Chen, Ruiqing Zhou, Yumiao Li, Fangfang Yang, Shilin Xu, Caixia Wang, Wei Zhou, Tingfen Deng, Shiyi Pan, Wenjian Mo, Shunqing Wang
Published in:
Infectious Diseases and Therapy
|
Issue 2/2024
Login to get access
Abstract
Introduction
In this single-center retrospective cohort study, we investigated the efficacy of letermovir in preventing Cytomegalovirus (CMV) infection in patients with aplastic anemia (AA) who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Methods
Based on whether or not letermovir was used for preventing CMV infection, the patients were categorized into two groups: letermovir and control groups. The overall survival (OS) rate and cumulative incidence of CMV infection during the first 100 days after allo-HSCT were evaluated. The study included 21 matched pairs of patients, identified through propensity score matching analysis, to compare CMV infection rates, treatment efficacy, and regression.
Results
The incidence of CMV infection within 100 days after transplantation was significantly lower in the letermovir group than in the control group (26.5 vs. 77.4%, respectively; P < 0.001), among a total of 87 patients who underwent the transplant. In the matched cohort of 21 patients with AA, the letermovir group also showed a significantly reduced cumulative incidence of CMV infection (14.3 vs. 90.5% in the control group; P < 0.001). Compared to the control group, patients with CMV infection in the letermovir group had lower CMV-DNA load and a shorter clearance time. However, there was no significant difference in OS between both groups (P = 0.34).
Conclusions
Letermovir effectively prevents CMV infection in allo-HSCT recipients with AA and demonstrates a high safety profile.